Fulcrum S-4 Amendment Adds HSR Clearance and Slate Phase 1 Trial Launch to Reverse Merger
FULC sits 33% above its 52-week low of $2.83.
Summary
Fulcrum's S-4 amendment confirms HSR antitrust clearance and Slate's Phase 1 trial launch for SLTE-1009, moving the reverse merger closer to completion.
Key Events · M&A and Partnerships · FULC
-
HSR Antitrust Clearance Obtained
The HSR Act waiting period expired at 11:59 p.m. Eastern Time on September 28, 2026, removing a key regulatory condition to closing the Fulcrum-Slate merger.
-
Slate Phase 1 Trial Initiated
Slate initiated its Phase 1 clinical trial of SLTE-1009 in healthy volunteers in Australia in August 2026, following Australian regulatory clearance in July 2026.
-
Fulcrum Workforce Reduced to 8 Employees
As of September 30, 2026, Fulcrum had only eight full-time employees, down from nine previously disclosed, highlighting the urgency of completing the merger.
-
Merger Background Disclosed
The S-4 amendment reveals Fulcrum contacted 62 potential counterparties, received 13 non-binding indications of interest, and prioritized 6 before selecting Slate.
Analysis · FULC · Life Sciences
This Amendment No. 1 to the S-4 materially advances the Fulcrum-Slate reverse merger timeline. The HSR waiting period expired September 28, 2026, clearing a key regulatory hurdle. Slate also initiated its Phase 1 trial of SLTE-1009 in Australia in August 2026, de-risking the lead asset that will become the combined company's core program. The filing also reveals Fulcrum's workforce has shrunk to just eight employees, underscoring the urgency of completing the transaction. The detailed merger background section — including outreach to 62 counterparties and 13 indications of interest — provides new transparency into the board's strategic alternatives process.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FULC was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286.1M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.